Aytu BioPharma (STU:AY20) Total Liabilities : €81.62 Mil (As of Dec. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Aytu BioPharma Total Liabilities?

Aytu BioPharma's Total Liabilities for the quarter that ended in Dec. 2024 was €81.62 Mil.

Aytu BioPharma's quarterly Total Liabilities declined from Jun. 2024 (€83.96 Mil) to Sep. 2024 (€77.49 Mil) but then increased from Sep. 2024 (€77.49 Mil) to Dec. 2024 (€81.62 Mil).

Aytu BioPharma's annual Total Liabilities increased from Jun. 2022 (€88.28 Mil) to Jun. 2023 (€89.63 Mil) but then declined from Jun. 2023 (€89.63 Mil) to Jun. 2024 (€83.96 Mil).

Aytu BioPharma Total Liabilities Historical Data

The historical data trend for Aytu BioPharma's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aytu BioPharma Total Liabilities Chart

Aytu BioPharma Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

Total Liabilities

Get a 7-Day Free Trial

51.75

106.32

88.28

89.63

83.96

Aytu BioPharma Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Total Liabilities	Get a 7-Day Free Trial															90.23	90.24	83.96	77.49	81.62

Aytu BioPharma Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Aytu BioPharma's Total Liabilities for the fiscal year that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	57.81	+	(10.105	+	16.047
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	83.96

Total Liabilities	=	Total Assets (A: Jun. 2024 )	-	Total Equity (A: Jun. 2024 )
	=	109.71	-	25.748
	=	83.96

Aytu BioPharma's Total Liabilities for the quarter that ended in Dec. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	61.166	+	(9.534	+	10.916
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	81.62

Total Liabilities	=	Total Assets (Q: Dec. 2024 )	-	Total Equity (Q: Dec. 2024 )
	=	110.997	-	29.381
	=	81.62

Aytu BioPharma Total Liabilities Related Terms

Thank you for viewing the detailed overview of Aytu BioPharma's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Aytu BioPharma Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aytu BioPharma Inc (STU:AY20) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

AYTU:USA 0A8M:UK

Address

7900 East Union Avenue, Suite 920, Denver, CO, USA, 80237

Website

https://www.aytubio.com

Aytu BioPharma Inc is a specialty pharmaceutical company with a commercial portfolio of prescription therapeutics and consumer health products. The company's primary prescription products treat attention deficit hyperactivity disorder and other common pediatric conditions. It is building a complementary therapeutic development pipeline including a prospective treatment (AR101/enzastaurin) for vascular Ehlers-Danlos Syndrome, a rare genetic disease resulting in high morbidity and a significantly shortened lifespan. The company operates in two segments Rx Segment, consisting of prescription pharmaceutical products and Consumer Health segments of which the company generates maximum revenue from the Rx segment.

Aytu BioPharma Headlines

No Headlines